SCHEDULE: Redmile Group Increases Stake in Shattuck Labs

Redmile Group, LLC and affiliates increased their beneficial ownership in Shattuck Labs, Inc. through warrant exercises and participation in an underwritten offering.

Summary

• Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments II, L.P. (RBI II) filed an amendment to their Schedule 13D regarding Shattuck Labs, Inc.
• The reporting persons exercised pre-funded warrants and common warrants, and participated in an underwritten offering of common stock and pre-funded warrants.
• The aggregate exercise price paid for warrant exercises was approximately $4,444,022.
• An additional $3,999,900 was utilized to acquire pre-funded warrants in an underwritten offering.
• The reporting persons now beneficially own 9,819,084 shares of common stock, representing 9.9% of the class.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal of institutional support, as the investor is actively increasing their financial commitment to the company.

Positives

• Significant capital commitment by a major institutional investor, signaling confidence in the issuer's long-term prospects.
• Successful execution of warrant exercises and participation in the company's underwritten offering.

Negatives

• Increased concentration of ownership by a single institutional group, which may impact future liquidity or voting dynamics.

Risks

• Beneficial ownership is subject to a 9.99% ownership limitation, which restricts the immediate conversion of all held warrants.
• Market volatility associated with the issuer's common stock price could impact the value of the warrants held.

Future Outlook

The reporting persons intend to continue to monitor their investment in the Issuer and may, from time to time, acquire additional securities or dispose of securities depending on market conditions and other factors.

Management Comments

• The reporting persons disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest.

Industry Context

StockSavvy.ai notes that this filing reflects a common trend in the biotechnology sector where institutional investors provide follow-on capital to support clinical-stage companies through public offerings and warrant exercises.

Comparison to Industry Standards

• The 9.9% ownership threshold is a standard benchmark for institutional investors to maintain significant influence without triggering certain regulatory complexities associated with higher ownership levels.
• The use of pre-funded warrants is a standard mechanism in biotech financing to allow investors to increase equity stakes while managing immediate beneficial ownership limitations.

Stakeholder Impact

• Shareholders may view the increased institutional backing as a vote of confidence.
• The issuance of additional shares and warrants may result in dilution for existing shareholders.

Next Steps

• Continued monitoring of the Issuer's performance and market conditions.
• Potential future adjustments to the investment position based on strategic objectives.

Key Dates

Recommendation

The filing indicates strong institutional support, which is generally positive, but the associated dilution from warrant exercises and new share issuance warrants a cautious hold until further clinical or operational milestones are achieved.

Keywords

Shattuck Labs, Redmile Group, Schedule 13D, Biotech, Warrants, Equity Offering